drugset

drugset / Trial / NCT02968368

Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease

NCT02968368 ↗

Phase 3 Completed 167 enrolled Shield Therapeutics

RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the efficacy of oral ferric maltol compared with placebo in the treatment of IDA in subjects with CKD

Timeline

Start: 2016-12-01
Primary completion: 2018-01-18
Completion: 2018-10-10

Publications

Pergola PE, Kopyt NP. Oral Ferric Maltol for the Treatment of Iron-Deficiency Anemia in Patients With CKD: A Randomized Trial and Open-Label Extension. Am J Kidney Dis. 2021 Dec;78(6):846-856.e1. doi: 10.1053/j.ajkd.2021.03.020. Epub 2021 May 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ferric maltol	Small molecule	30 mg	Oral

Indications